PDF下载 ( 1957 KB)
Value of FibroScan in the diagnosis of progressive liver fibrosis in patients with chronic hepatitis C and related influencing factors
-
摘要: 目的分析FibroScan对慢性丙型肝炎进展期肝纤维化的诊断效能并探讨其影响因素。方法选取2015年6月-2018年6月于首都医科大学附属北京佑安医院就诊的慢性丙型肝炎患者,均完成肝穿刺病理检查。根据METAVIR评分系统进行纤维化分期,分为F1～F4期。收集患者一般资料,所有患者进行肝脏弹性检测和肝功能、血常规、病毒定量等检测,利用公式计算APRI及FIB-4。不符合正态分布的计量资料多组间比较采用Kruskal-Wallis H秩和检验,进一步两两比较采用Wilcoxon秩和检验。相关性检验采用Spearman秩相关分析。利用受试者工作特征曲线（ROC曲线）分析3种无创诊断方法对肝纤维化的诊断价值,采用STATA验证3种无创诊断方法是否存在统计学差异。结果入组患者共131例,其中男60例（45. 80%）,女71例（54. 20%）,平均54. 00（45. 00～58. 25）岁。FibroScan水平为7. 80（5. 60～14. 30） kPa,APRI水平为0. 63（0. 37～1. 28）,FIB-4水平为2. 28（1. 43～3. 60）。随着肝纤维化分期的进展,...Abstract: Objective To investigate the diagnostic efficacy of FibroScan in the diagnosis of progressive liver fibrosis in patients with chronic hepatitis C and related influencing factors. Methods A total of 131 patients with chronic hepatitis C who attended Beijing YouAn Hospital, Capital Medical University from June 2015 to June 2018 were enrolled, and all of them underwent liver biopsy. Fibrosis stage was defined as F1 to F4 stages according to the METAVIR scoring system. General information was collected, and liver stiffness measurement ( LSM) , liver function test, routine blood test, and viral quantification were performed for all patients. Aspartate aminotransferase-to-platelet ratio index ( APRI) and fibrosis-4 ( FIB-4) were calculated according to equations. The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous between multiple groups, and the Wilcoxon rank-sum test was used for further comparison between two groups. A Spearman correlation analysis was performed. The receiver operating characteristic ( ROC) curve was used to analyze the value of three noninvasive methods in the diagnosis of liver fibrosis, and STATA was used to investigate whether there was a significant difference between the three methods. Results A total of 131 patients were enrolled, with 60 male patients ( 45. 80%) and 71 female patients ( 54. 20%) , and the mean age was 54. 00 ( 45. 00-58. 25) years. The median values of FibroScan, APRI, and FIB-4 were 7. 80 ( 5. 60-14. 30) kPa, 0. 63 ( 0. 37-1. 28) , and 2. 28 ( 1. 43-3. 60) , respectively. LSM gradually increased with the progression of liver fibrosis, and there was a significant difference between groups ( H = 47. 83, P < 0. 01) . For progressive liver fibrosis ( ≥F3 stage) , FibroScan had a larger area under the ROC curve ( AUC) than APRI and FIB-4, and further analysis based on STATA showed that there was a significant difference in AUC between FibroScan and APRI ( P < 0. 01) , while there was no significant difference in AUC between FibroScan and FIB-4 ( P = 0. 07) . FibroScan was correlated with alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , gamma-glutamyl transpeptidase ( GGT) , and platelet count ( r = 0. 271, 0. 507, 0. 444, and-0. 263, all P < 0. 01) . The AUC of FibroScan was not signifi-cantly improved after adjustment for the above influencing factors. Conclusion FibroScan has good diagnostic efficacy in the diagnosis of progressive liver fibrosis in patients with hepatitis C, with better comprehensive diagnostic efficacy than APRI and FIB-4. The accuracy of FibroScan in diagnosis is not affected by the indicators such as ALT, AST, and GGT.
-
Key words:
- hepatitis C, chronic /
- liver cirrhosis /
- elasticity imaging techniques /
- diagnosis
-
[1] LAVANCHY D. Evolving epidemiology of hepatiti C virus[J].Clin Microbiol Infect, 2011, 17 (2) :107-115. [2] MESSINA JP, HUMPHREYS I, FLAXMAN A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J].Hepatology, 2015, 61 (1) :77-87. [3] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69 (2) :461-511. [4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979. [5] STERLING RK, LISSEN E, CLUMECK N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology, 2006, 43 (6) :1317-1325. [6] WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38 (2) :518-526. [7] BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C[J]. Hepatology, 1996, 24 (2) :289-293. [8] SANDRIN L, FOURQUET B, HASQUENOPH JM, et al. Transient elastography:A new noninvasive method for assessment of hepatic fibrosis[J]. Ultrasound Med Biol, 2003, 29 (12) :1705-1713. [9] GUO JS. The critical importance of diagnosing and treating liver fibrosis[J]. J Clin Hepatol, 2018, 34 (1) :16-19. (in Chinese) 郭津生.重视肝纤维化的诊治[J].临床肝胆病杂志, 2018, 34 (1) :16-19. [10] KIM BK, KIM HS, PARK JY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B[J].PLo S One, 2012, 7 (7) :e41964. [11] PINZANI M, VIZZUTTI F, ARENA U, et al. Technology Insight:Noninvasive assessment of liver fibrosis by biochemical scores and elastography[J]. Nat Clin Pract Gastroenterol Hepatol, 2008, 5 (2) :95-106. [12] TAN YJ, JI D, NIU XX, et al. Frequency and determinants of liver stiffness measurement failure[J]. J Med Res, 2012, 41 (11) :30-33. (in Chinese) 谭有娟, 纪冬, 牛小霞, 等.瞬时弹性成像检测肝硬度失败的因素及分析[J].医学研究杂志, 2012, 41 (11) :30-33. [13] GASTERA L, FOUCHER J, BERNARD PH, et al. Pitfal s of liver stiffness measurement:A 5-year prospective study of 13, 369 examinations[J]. Hepatology, 2010, 51 (3) :828-835. [14] OGAWA E, FURUSYO N, TOYODA K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection:Non-invasive, quantitative assessment of liver fibrosis[J]. Hepatol Res, 2007, 37 (12) :1002-1010. [15] CHENG PN, CHIU HC, CHIU YC, et al. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community[J]. PLo S One, 2018, 13 (11) :e0206947. [16] BAZERBACHI F, HAFFAR S, WANG Z, et al. Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals[J]. Clin Gastroenterol Hepatol, 2019, 17 (1) :54-64. e1. [17] CHAN HL, WONG GL, CHOI PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B[J]. J Viral Hepat, 2009, 16 (1) :36-44. [18] WONG GL, WONG VW, CHOI PC, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases[J]. Clin Gastroenterol Hepatol, 2008, 6 (9) :1027-1035. 期刊类型引用(7)
1. 陈茜蕾，慕永平，刘平. 肝硬化门静脉高压症中医证候病机特点及治疗进展. 中华中医药杂志. 2023(06): 2734-2738 . 
百度学术2. 高丽芳. 活血化瘀通络法治疗肝硬化合并上消化道出血肝脾血瘀证的临床观察. 山西中医药大学学报. 2023(06): 636-640 . 百度学术3. 冯颖，时克，张晓华，杨莉，王宪波. 抗肝纤维化中药治疗对肝硬化并发肠系膜上静脉栓塞患者预后的影响. 临床肝胆病杂志. 2022(07): 1534-1539 . 
本站查看4. 徐珍，梁斌. 裸花紫珠颗粒辅助治疗慢性乙肝肝硬化所致食管胃静脉曲张出血的临床观察. 江西医药. 2022(08): 940-942 . 百度学术5. 齐小泉. 奥曲肽联合去氨加压素治疗肝硬化合并食管胃底静脉曲张破裂出血的临床效果. 临床合理用药杂志. 2021(35): 95-97 . 百度学术6. 郑延和. 复方甘草酸苷联合奥曲肽对肝硬化上消化道出血的疗效. 甘肃医药. 2021(12): 1093-1095 . 百度学术7. 王波，曹雪，唐航，李子瑜，刘楷煜，牛犇. 针刀疗法联合中药熏蒸治疗旋前圆肌综合征. 吉林中医药. 2020(01): 124-127 . 百度学术其他类型引用(2)
-
百度学术
下载:
